NCT04313166View on ClinicalTrials.gov

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

November 18, 2021

Study Completion Date

February 15, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Cu(II)ATSM

cooper-containing synthetic small molecule

Trial Locations (1)

Unknown

Macquarie University, Macquarie Park

Sponsors
All Listed Sponsors
lead

Collaborative Medicinal Development Pty Limited

INDUSTRY

NCT04313166 - Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 | Biotech Hunter | Biotech Hunter